
NASDAQHealthcareBiotechnology
Latest quote
$0.3339
−$0.0131 · -3.78%
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Previous close
$0.3339
−$0.0131 · -3.78%
Regular session · ET · Market data may be delayed.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Day range
Current $0.3339
52-week range
Current $0.3339
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
59
Mixed
Risk
84
Extreme Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Day range
Current $0.3339
52-week range
Current $0.3339
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 5M USD | — | 668K USD | — | — |
| Gross profit | −5M USD | — | −668K USD | — | — |
| Research and development | 176.07M USD | 200.93M USD | 142.72M USD | 104.75M USD | 212.78M USD |
| Selling, general, and administrative | 60.09M USD | 62.54M USD | 44.81M USD | 31.12M USD | 24.55M USD |
| Operating expenses | 236.16M USD | 263.46M USD | 187.53M USD | 135.87M USD | 237.32M USD |
| Interest income | 8.34M USD | 19.93M USD | 16.61M USD | 4.56M USD | — |
| Interest expense | 3.22M USD | — | — | — | — |
| Depreciation and amortization | 208K USD | 631K USD | 668K USD | 594K USD | 538K USD |
| Operating income | −241.16M USD | −263.46M USD | −188.19M USD | −135.87M USD | −237.32M USD |
| Net income | −236.93M USD | −243.79M USD | −235.93M USD | −130.9M USD | −237.31M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$4.50
1247.71% upsidePrice history unavailable
High $5.00Average $4.50Low $4.00Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI994.13K0.00%689.3B USD0.03%$340.02-3.52%
iShares Russell 2000 ETFIWM876.27K0.00%71.54B USD0.19%$256.61-2.88%
Vanguard Extended Market ETFVXF413.49K0.00%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO370.94K0.00%12.73B USD0.24%$320.43-3.57%
Vanguard Russell 2000 ETFVTWO222.32K0.00%16.8B USD0.06%$103.76-2.76%
iShares Biotechnology ETFIBB207.97K0.00%10.53B USD0.44%$199.54-2.05%
Schwab U.S. Small-Cap ETFSCHA186.01K0.00%20.45B USD0.03%$30.51-2.83%
iShares Micro-Cap ETFIWC111.41K0.01%1.09B USD0.60%$157.87-3.19%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
iShares Biotechnology ETFIBB
Schwab U.S. Small-Cap ETFSCHA
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.